Afabicin | 1518800-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Afabicin
• 英文别名: [6-[(E)-3-[methyl-[(3-methyl-1-benzofuran-2-yl)methyl]amino]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]methyl dihydrogen phosphate
• CAS: 1518800-35-5
• 化学式: C₂₃H₂₄N₃O₇P
• 分子量: 485.4
• InChiKey: HFYMDQMXVPJNTH-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS<br/>[FR] ANTIBIOTIQUES EFFICACES CONTRE LES PATHOGÈNES GRAM-NÉGATIFS
  申请人：UNIV ILLINOIS

  公开号：WO2019177975A1

  公开（公告）日：2019-09-19

  Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative bacterial infections. Compounds selected for conversion to potential Gram-negative antibacterial compounds were identified based on compounds having low globularity and low flexibility. Amine substituents were then strategically added to the selected compounds to provide compounds having antibacterial activity against Gram-negative bacteria.

  本文披露了在革兰氏阴性细菌中积累的抗菌化合物，制备这些化合物的方法，以及利用这些化合物抑制或杀灭微生物，以及治疗微生物感染的方法，如革兰氏阴性细菌感染。选择用于转化为潜在革兰氏阴性抗菌化合物的化合物是基于具有低球形度和低柔性的化合物。然后在所选的化合物中策略性地添加氨基取代基，以提供对革兰氏阴性细菌具有抗菌活性的化合物。
• Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
  申请人：Debiopharm International SA

  公开号：US10035813B2

  公开（公告）日：2018-07-31

  In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.

  本公开内容部分涉及具有显著溶解度和生物利用度特征的(E)-N-甲基-N-((3-甲基苯并呋喃-2-基)甲基)-3-(7-氧代-5,6,7,8-四氢-1,8-萘啶-3-基)丙烯酰胺化合物的原药衍生物。
• Medicament for treatment of diabetic foot infections
  申请人：Debiopharm International S.A.

  公开号：US10751351B2

  公开（公告）日：2020-08-25

  The present invention provides means and methods for treating diabetic foot infections. In particular, drug compounds are provided that combine a high therapeutic activity against Staphylococcus Spp. bacteria with a high degree of bone penetration and vasodilatory effects. This unique combination of properties allows to accomplish high local concentrations of the drug at the site of infection even in diabetic foot patients typically having poor blood perfusion at the site of infection.

  本发明提供了治疗糖尿病足感染的手段和方法。特别是，本发明提供的药物化合物结合了对葡萄球菌属细菌的高治疗活性、高骨穿透性和血管扩张作用。这种独特的特性组合可以使药物在感染部位达到较高的局部浓度，即使是感染部位血液灌流较差的糖尿病足患者也不例外。
• PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE
  申请人：Debiopharm International SA

  公开号：EP2861608B1

  公开（公告）日：2019-04-24
• MEDICAMENT FOR TREATMENT OF DIABETIC FOOT INFECTIONS
  申请人：Debiopharm International SA

  公开号：EP3419628A1

  公开（公告）日：2019-01-02